Low- and middle-income countries (LMICs) need to build their domestic drug-manufacturing capabilities beyond just vaccine production (see Nature 602, 184; 2022). Innovative production systems are emerging that could markedly increase their access to vaccines and therapeutics (see go.nature.com/3wjijgb).
Competing Interests
K.R.L. is an owner, shareholder and employee of Sunflower Therapeutics PBC. Ameer Basrai is an employee and shareholder of Roivant Sciences. Anthony Bogachev is an employee of Roivant Social Ventures and a shareholder of Rovant Sciences. F.R. is a consultant for the Bill & Melinda Gates Foundation and a member of the board of directors of VaxThera, a Sura Company.
More News
How I fled bombed Aleppo to continue my career in science
Powerful ‘nanopore’ DNA sequencing method tackles proteins too
US funders to tighten oversight of controversial ‘gain-of-function’ research